Rinsho Shinkeigaku (Clinical Neurology)

Symposium 2

Management of intracranial hemorrhage during anticoagulant therapy with warfarin or novel anticoagulants

Masahiro Yasaka, M.D., Ph.D. and Yasushi Okada, M.D., Ph.D.

Cerebrovascular Medicine, Cerebrovascular Center, Research Institute, Kyushu Medical Center

Novel anticoagulants including dabigatran and rivaroxaban have lower incidence of intracranial hemorrhage compared to warfarin. Therefore, in patients with high risks for intracranial hemorrhage, such as past history of brain infarction, brain hemorrhage, microbleeds on MRI, or concomitant use of antiplatelet, novel anticoagulant may be appropriate. Irrespective of any anticoagulants, it is essential to manage controllable risk factors, such as hypertension, diabetes mellitus, smoking habit, and excessive alcohol drinking. Combination therapy of other antithrombotic agents had better be avoided as long as possible. In emergency of hemorrhage complications, discontinuation of anticoagulants, procedure to stop bleeding, and appropriate intravenous infusion is quite important and lowering blood pressure is also important when intracranial hemorrhage happens. There is no antidote to novel anticoagulants. However, oral activated charcoal may be effective if early after taking medicine. The dabigatran can be dialysed. Some experimental evidences support the role of prothrombin complex concentrate to stop bleeding. However, their usefulness in clinical setting has not been established. Collecting and analyzing data regarding immediate reversal of novel anticoagulants is required in near future.
Full Text of this Article in Japanese PDF (225K)

(CLINICA NEUROL, 52: 1113|1116, 2012)
key words: warfarin, dabigatran, rivaroxaban, intracranial hemorrhage, prothrombin complex concentrate

(Received: 24-May-12)